Login / Signup

Concomitant Use of Sulfonylureas and β-Blockers and the Risk of Severe Hypoglycemia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study.

Jenny DimakosYing CuiRobert W PlattChristel RenouxKristian B FilionAntonios Douros
Published in: Diabetes care (2022)
β-blockers could further increase the risk of severe hypoglycemia when used concurrently with sulfonylureas. β-blocker cardioselectivity did not seem to play a major role in this regard.
Keyphrases
  • angiotensin converting enzyme
  • type diabetes
  • early onset
  • angiotensin ii
  • glycemic control
  • drug induced
  • metabolic syndrome